Google's Stock Soars as Gemini Robotics Debuts and DeepMind Strengthens AI Leadership

In recent market movements, Google A (GOOGL) experienced a 2.88% increase last week, marking a four-day streak that accumulated an impressive 8.08% gain over this period. Over the past week, the company's stock ascended by 7.14%, despite a year-to-date decline of 5.48%. On June 27, 2025, Google A traded with a volume of 1.08 billion shares, reaching a value of $191.09 billion, which represented a massive 248.50% increase from the previous day's trading volume.

On the same day, Google A's share price rose by 2.88%, closing at $178.53, contributing to a five-day gain of 7.14%. Although the stock has seen a dip of 5.69% since the start of the year, its performance in June showed a positive trend, with a 3.95% rise. Over the past 52 weeks, the stock has decreased by 1.99%, reflecting the fluctuations and challenges in the market.

Recently, Google introduced an innovative robotics model, Gemini Robotics On-Device. This development enhances the practical application of Gemini 2.0's multi-modal reasoning and real-world understanding capabilities, enabling complex tasks to be executed adeptly. This advancement aligns with Google's ongoing efforts to integrate cutting-edge technology into tangible, everyday applications.

In a significant personnel development, renowned computer vision expert Ke Ming He announced his part-time association with Google's DeepMind as a distinguished scientist. This strategic move not only bolsters Google's leadership in the AI sector but also signifies potential groundbreaking advancements in AI technology.

Furthermore, Google DeepMind recently unveiled AlphaGenome, an AI model designed to predict the impact of genetic mutations with striking precision. This model acts as an AI microscope for human DNA, providing high-resolution context for long sequences and offering comprehensive multi-modal predictions. AlphaGenome aims to revolutionize the understanding of gene regulation with widespread potential applications in disease research and synthetic biology.